山東華鵬(603021.SH)半年度業績盈轉虧至1195.18萬元
格隆匯8月23日丨山東華鵬(603021.SH)發佈2019年半年度報告,實現營業收入3.73億元,同比下降6.57%;歸屬於上市公司股東的淨虧損1195.18萬元,上年同期盈利298.17萬元;基本每股虧損0.04元。
隨着公司產品輕量化工作的推進,江蘇石島針對小口壓吹產品試製生產線存在的制約因素,通過收集小口壓吹成型資料,多次組織生產技術人員對小口壓吹工藝進行交流、討論與分析,逐項梳理,逐項落實,確定關鍵參數,最終一次性突破小口壓吹生產工藝難關,填補了公司此項技術的空白,豐富了技改創新成果,標誌着公司在新技術新工藝的應用和掌握方面又有一個質的突破,為公司產品適應激烈的市場競爭提供技術保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.